Pusalkar S - Search Results

1

The Current State of Biotransformation Science - Industry Survey of In Vitro and In Vivo Practices, Clinical Translation, and Future Trends.

Savaryn JP, Coe K, Cerny MA, Colizza K, Moliner P, King L, Ma B, Atherton J, Auclair A, Cancilla MT, Eno M, Jurva U, Yue Q, Zhu SX, Freiberger E, Zhong G, Barlock B, Nachtigall J, Laboureur L, Pusalkar S, Guo R, Niehues M, Hauri S, Carreras ET, Maurer C, Prakash C, Jenkins GJ. Savaryn JP, et al. Among authors: pusalkar s. Pharm Res. 2024 Nov 4. doi: 10.1007/s11095-024-03787-y. Online ahead of print. Pharm Res. 2024. PMID: 39496990

2

Metabolism and Excretion of [¹⁴C]Mobocertinib, a Selective Covalent Inhibitor of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations, in Healthy Male Subjects.

Chen H, Shah A, Kato S, Griffin R, Zhang S, Pusalkar S, Cohen L, Li Y, Chowdhury SK, Zhu SX. Chen H, et al. Among authors: pusalkar s. Drug Metab Dispos. 2024 Sep 16;52(10):1115-1123. doi: 10.1124/dmd.124.001841. Drug Metab Dispos. 2024. PMID: 39038951

3

Clinical and Nonclinical Disposition and In Vitro Drug-Drug Interaction Potential of Felcisetrag, a Highly Selective and Potent 5-HT₄ Receptor Agonist.

Pusalkar S, Chowdhury SK, Czerniak R, Zhu X, Li Y, Balani SK, Ramsden D. Pusalkar S, et al. Eur J Drug Metab Pharmacokinet. 2022 May;47(3):371-386. doi: 10.1007/s13318-021-00751-8. Epub 2022 Feb 14. Eur J Drug Metab Pharmacokinet. 2022. PMID: 35157234 Free PMC article.

4

Metabolism, Excretion and Pharmacokinetics of MLN3897, a CCR1 Antagonist, in Humans.

Pusalkar S, Plesescu M, Milton M, Balani SK, Chowdhury S, Prakash S. Pusalkar S, et al. Drug Metab Lett. 2016;10(1):22-37. doi: 10.2174/1872312809666150602152423. Drug Metab Lett. 2016. PMID: 26031460 Clinical Trial.

5

Analysis of the Bile Acid Composition in a Fibroblast Growth Factor 19-Expressing Liver-Humanized Mouse Model and Its Use for CYP3A4-Mediated Drug-Drug Interaction Studies.

Mezler M, Jones RS, Sangaraju D, Goldman DC, Hoffmann M, Heikkinen AT, Mannila J, Chang JH, Foquet L, Pusalkar S, Chothe PP, Scheer N. Mezler M, et al. Among authors: pusalkar s. Drug Metab Dispos. 2023 Oct;51(10):1391-1402. doi: 10.1124/dmd.123.001398. Epub 2023 Jul 31. Drug Metab Dispos. 2023. PMID: 37524541

6

Biotransformation of [¹⁴C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces.

Pusalkar S, Plesescu M, Gupta N, Hanley M, Venkatakrishnan K, Wu JT, Xia C, Zhang X, Chowdhury S. Pusalkar S, et al. Cancer Chemother Pharmacol. 2018 Nov;82(5):803-814. doi: 10.1007/s00280-018-3671-z. Epub 2018 Aug 20. Cancer Chemother Pharmacol. 2018. PMID: 30128949 Clinical Trial.

7

Metabolism and Disposition of [¹⁴C]Pevonedistat, a First-in-Class NEDD8-Activating Enzyme Inhibitor, after Intravenous Infusion to Patients with Advanced Solid Tumors.

Bolleddula J, Chen H, Cohen L, Zhou X, Pusalkar S, Berger A, Sedarati F, Venkatakrishnan K, Chowdhury SK. Bolleddula J, et al. Among authors: pusalkar s. Drug Metab Dispos. 2022 Jul;50(7):989-997. doi: 10.1124/dmd.122.000842. Epub 2022 May 3. Drug Metab Dispos. 2022. PMID: 35504658

8

Sinusoidal Uptake Determines the Hepatic Clearance of Pevonedistat (TAK-924) as Explained by Extended Clearance Model.

Sandoval P, Chuang BC, Cohen L, Yoneyama T, Pusalkar S, Yucha RW, Chowdhury SK, Chothe PP. Sandoval P, et al. Among authors: pusalkar s. Drug Metab Dispos. 2022 Jul;50(7):980-988. doi: 10.1124/dmd.122.000836. Epub 2022 May 11. Drug Metab Dispos. 2022. PMID: 35545257

9

Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes.

Lu C, Gallegos R, Li P, Xia CQ, Pusalkar S, Uttamsingh V, Nix D, Miwa GT, Gan LS. Lu C, et al. Among authors: pusalkar s. Drug Metab Dispos. 2006 Apr;34(4):702-8. doi: 10.1124/dmd.105.008060. Epub 2006 Jan 27. Drug Metab Dispos. 2006. PMID: 16443666

10

Biotransformation Pathways and Metabolite Profiles of Oral [¹⁴C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors.

Pusalkar S, Zhou X, Li Y, Cohen L, Yang JJ, Balani SK, Xia C, Shyu WC, Lu C, Venkatakrishnan K, Chowdhury SK. Pusalkar S, et al. Drug Metab Dispos. 2020 Mar;48(3):217-229. doi: 10.1124/dmd.119.087338. Epub 2020 Jan 7. Drug Metab Dispos. 2020. PMID: 31911485 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters